

## **DIVERSA, Delivery Innovation for Versatile Solutions in Advanced Therapeutics**

Our drug delivery technology based on lipidic nanoemulsions allows for safe and physiological intracellular delivery of complex macromolecules (peptides, proteins and nucleic acids) and small hydrophobic molecules. The platform has broad and fresh IP protection and is fully scalable and regulatory compliant.

To translate our technology, we create DIVERSA, a spin-of company aiming to bridge the gap between molecules and patients, between drug discovery and clinical application. We want to create new opportunities to improve patients' quality of life.

Despite the discovery of many new targets and therapeutic molecules in labs around the world, less than 3% of them will make it to clinical stages. Most of these new molecules are discarded in the early stages of research, mostly because they cannot access the interior of the cell, where 3 out of 4 new molecules have their targets. We want to change that by overcoming the main barriers that limit the safe and efficient delivery of molecules to their target, improving their translation and contributing to the creation of new opportunities to solve current unmet clinical needs.